{"id":"W2078797757","doi":"10.1016/j.ejca.2008.10.022","title":"A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group","year":2008,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University of Ottawa; Queen's University; Ottawa Hospital","funders":"AstraZeneca","keywords":"Gemcitabine; Medicine; Pharmacokinetics; Cisplatin; Internal medicine; Nausea; Tolerability; Pharmacology; Phases of clinical research; Oncology; Chemotherapy; Gastroenterology; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006683627,0.0001792374,0.0008264511,0.000184302,0.00003966088,0.000003990526,0.0001013998,0.00001785643,0.00001352974],"category_scores_gemma":[0.0001060918,0.0001094208,0.000044873,0.000335733,0.0001156165,0.0001750819,0.00002721193,0.0001979143,4.264176e-9],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002045822,"about_ca_system_score_gemma":0.0012154,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.03090811,"about_ca_topic_score_gemma":0.08593115,"domain_scores_codex":[0.9971962,0.000497318,0.001259722,0.000200578,0.0007175845,0.0001285793],"domain_scores_gemma":[0.9975367,0.00009094368,0.001357282,0.0001058227,0.0008059446,0.0001033195],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006079781,0.008198417,0.9742256,0.0001687156,0.0004683062,0.00004242838,0.004208812,0.00124721,0.002059389,9.617116e-7,0.00002834441,0.003271968],"study_design_scores_gemma":[0.1188172,0.009853045,0.8683151,0.0005870589,0.000685916,0.000002820812,0.0004791286,0.0001188831,0.001022457,3.568618e-7,0.00002648763,0.00009148823],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9969829,0.0008884158,0.00001089633,0.00003909445,0.0002134005,0.001611055,0.0002319794,0.000001411133,0.00002089063],"genre_scores_gemma":[0.9993892,0.0003321622,0.0001061373,0.00003027949,0.00007563263,0.00002632681,0.000006089394,0.00002411328,0.000010057],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1127375,"threshold_uncertainty_score":0.9755452,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.032184655486618,"score_gpt":0.354291009153011,"score_spread":0.3221063536663931,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}